MYDA Advisors’s Bristol-Myers Squibb BMY Stock Holding History

MYDA Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7,500	Closed	-$388K	–	145
2024 Q3	$388K	Buy	+7,500	New	+$352K	0.09%	118

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MYDA Advisors's BMY Position: Q4 2024 in Review

MYDA Advisors sold out of Bristol-Myers Squibb (BMY) in Q4 2024, closing a stake of 7,500 shares — an estimated $388K sold.

MYDA Advisors first reported a position in BMY in Q3 2024 and held it in 1 quarter. The position peaked at $388K in Q3 2024. 2,486 funds tracked by Wall St. Rank hold BMY as of Q4 2024.

MYDA Advisors reported no remaining Bristol-Myers Squibb position as of Q4 2024 after selling out during the quarter.
MYDA Advisors sold 7,500 Bristol-Myers Squibb shares in Q4 2024, an estimated $388K.
MYDA Advisors first reported a position in Bristol-Myers Squibb in Q3 2024 and held it in 1 quarter.
MYDA Advisors's Bristol-Myers Squibb position peaked at $388K in Q3 2024.
2,486 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2024.

Based on MYDA Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.